6d
Pharmaceutical Technology on MSNRoyalty Pharma pays $250m for rights to Biogen’s lupus drugRoyalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...
We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...
The Muscular Dystrophy Association celebrates this new more accessible treatment option for people living with SMA. MDA - New ...
Royalty also holds rights on Biogen’s MS medication Tysabri (natalizumab) and spinal muscular atrophy drug Spinraza (nusinersen), acquired through agreements with Ionis and Perrigo. The deal ...
Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...
Biogen has made a further push into RNA-based ... the neurological disorder spinal muscular atrophy (SMA) – Spinraza (nusinersen) – is one result of that effort. The antisense oligonucleotide ...
Biogen has invested heavily in its Alzheimer ... at a time when its big selling SMA drug Spinraza (nusinersen) is facing increased competitive pressure. At the same time, Sage has struggled ...
Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results